TITLE:
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

CONDITION:
Ovarian Neoplasms

INTERVENTION:
TLK286 HCl for injection

SUMMARY:

      The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as
      compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat
      (ITT) populations.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion criteria include:

          -  Considered platinum refractory or resistant according to standard criteria

          -  Progressed during or following completion of one second-line treatment with
             Doxil/Caelyx or Hycamtin

          -  Histologically or cytologically confirmed diagnosis of epithelial cancer of the
             ovary, fallopian tube, or primary peritoneal cancer

          -  Measurable disease according to RECIST criteria with documented tumor progression

        Exclusion criteria include:

          -  Treatment with second-line chemotherapy other than Doxil/Caelyx or Hycamtin

          -  History of whole pelvis radiation therapy within 12 months of enrollment

          -  Clinically significant cardiac disease

          -  Evidence of gross hematuria at the time of study entry

          -  Any signs of intestinal obstruction interfering with nutrition at the time of study
             entry

          -  Pregnant or lactating women
      
